+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Minimally Invasive Treatment of Lung Cancer Market - Global Forecast 2026-2032- Product Image
Minimally Invasive Treatment of Lung Cancer Market - Global Forecast 2026-2032- Product Image
Sale

Minimally Invasive Treatment of Lung Cancer Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6283388
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Minimally Invasive Lung Cancer Treatment: Executive Overview

Minimally invasive treatment of lung cancer encompasses image-guided biopsies, bronchoscopic diagnosis and therapy, video-assisted and robotic thoracic surgery, stereotactic radiation, and selected endovascular or ablative procedures. These approaches are used to improve diagnostic precision, reduce surgical trauma, shorten recovery, and support treatment of patients who may not tolerate conventional open procedures. Clinical adoption depends on stage, histology, tumor location, patient fitness, institutional expertise, and access to imaging, pathology, operating rooms, and multidisciplinary care.

Clinical and Operational Shifts Reshaping Treatment Pathways

Treatment is shifting toward earlier diagnosis, tissue-preserving intervention, and coordinated multidisciplinary decision-making. Advances in low-dose computed tomography screening, navigational bronchoscopy, endobronchial ultrasound, cone-beam imaging, video-assisted thoracic surgery, robotic platforms, stereotactic body radiation therapy, and percutaneous ablation are expanding the range of less invasive options. At the same time, enhanced recovery protocols, molecular testing, liquid-biopsy research, and outpatient care models are influencing how patients move from detection to definitive treatment and surveillance.

Artificial Intelligence Improves Detection, Planning, and Follow-Up

Artificial intelligence is being applied to assist pulmonary nodule detection, imaging interpretation, risk stratification, bronchoscopy navigation, radiation planning, pathology review, and postoperative monitoring. Its practical value depends on representative training data, transparent validation, interoperability with clinical systems, and clinician oversight. AI can help prioritize suspicious findings and standardize workflows, but it does not replace tissue diagnosis, multidisciplinary assessment, or informed clinical judgment. Governance, bias monitoring, cybersecurity, and clear accountability remain essential as deployment expands.

Regional Insights: Uneven Access Shapes Minimally Invasive Care

North America generally benefits from advanced imaging, specialized thoracic centers, screening infrastructure, and broad availability of minimally invasive surgery and stereotactic radiation, although rural access and affordability remain concerns. Europe combines strong clinical research and structured health systems with variation in reimbursement, screening policy, and equipment availability across countries. Asia-Pacific shows rapid capability development alongside substantial differences between metropolitan and rural care; Japan, South Korea, Australia, China, and India each reflect distinct regulatory and delivery environments. Latin America is expanding specialist capacity but continues to face unequal access to diagnostics and advanced equipment. The Middle East is developing tertiary-care infrastructure, while Africa remains constrained by late presentation, limited screening, pathology capacity, and shortages of trained specialists.

Group Insights: Policy and Economic Alliances Influence Adoption

ASEAN countries face varied healthcare resources and benefit from regional training, referral networks, and technology-transfer initiatives. BRICS members span advanced urban centers and major access gaps, making local manufacturing, workforce development, and tiered referral systems important. The European Union is influenced by cross-border health cooperation, medical-device regulation, data governance, and differing national reimbursement decisions. G7 systems typically have strong research and specialist capabilities but must address aging populations, workforce pressure, cost containment, and rural inequity. GCC countries are investing in tertiary hospitals, digital health, and specialist recruitment, while NATO members show diverse clinical infrastructures but share interests in resilient supply chains, emergency preparedness, and interoperable health information.

Country Insights: Capability, Screening, and Reimbursement Differ Widely

Australia combines established thoracic services with geographic access challenges. Brazil and Mexico are working to extend specialist care beyond major cities. Canada and the United States have advanced procedural capabilities, though rural access, insurance coverage, and affordability differ. China is expanding high-end hospital capacity and domestic medical technology, while India is developing specialist networks amid pronounced urban-rural variation. Japan and South Korea have mature imaging and procedural ecosystems. France, Germany, Italy, Spain, and the United Kingdom have strong hospital-based expertise, with differences in waiting times, procurement, screening policy, and reimbursement. Russia’s access is shaped by regional infrastructure and equipment availability. Across all countries, earlier detection, pathology turnaround, multidisciplinary coordination, and trained personnel are central determinants of outcomes.

Priorities for Leaders: Build Integrated, Equitable, Evidence-Based Pathways

Industry leaders should align device, imaging, radiation, pathology, and data strategies with clearly defined clinical pathways rather than treating procedures as stand-alone technologies. Priorities include investing in clinician training, validating outcomes across diverse populations, strengthening referral networks, integrating molecular and imaging data, and designing solutions that function in resource-constrained settings. Organizations should establish prospective registries, monitor complications and patient-reported recovery, support interoperable records, and use AI under documented governance controls. Partnerships with hospitals, payers, regulators, and professional societies can improve evidence generation, appropriate reimbursement, and equitable access.

Research Methodology: Evidence-Based Assessment of Clinical Adoption

This executive summary uses the defined market scope of minimally invasive treatment of lung cancer and synthesizes established clinical, technological, policy, and health-system considerations. The assessment is organized by treatment pathway, enabling technology, geography, economic grouping, and country context. It prioritizes evidence from clinical guidelines, peer-reviewed research, regulatory materials, health-system publications, and documented institutional practice. Interpretations distinguish clinical capability from access and avoid unsupported market estimates, forecasts, company comparisons, or claims of uniform adoption. Regional and country observations are presented as contextual patterns rather than rankings.

Conclusion: Coordinate Innovation With Access, Evidence, and Patient Safety

Minimally invasive lung cancer treatment is progressing through the convergence of earlier detection, image-guided intervention, advanced surgery, focused radiation, molecular characterization, and digitally supported care. The benefits will not be distributed evenly unless health systems address workforce shortages, diagnostic delays, infrastructure gaps, affordability, and rural access. Sustainable progress requires evidence-led technology adoption, responsible AI, multidisciplinary coordination, and measurement of outcomes that matter to patients. Leaders that connect innovation with training, reimbursement, quality assurance, and equitable delivery will be better positioned to improve care across diverse health systems.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Minimally Invasive Treatment of Lung Cancer Market, by Treatment Modality
7.1. Introduction
7.2. Video-Assisted Thoracoscopic Surgery (VATS)
7.3. Robotic-Assisted Thoracic Surgery (RATS)
7.4. Radiofrequency Ablation (RFA)
7.5. Microwave Ablation (MWA)
7.6. Cryoablation
7.7. Stereotactic Body Radiation Therapy (SBRT)
8. Minimally Invasive Treatment of Lung Cancer Market, by Cancer Stage
8.1. Introduction
8.2. Early-Stage (I-II)
8.3. Locally Advanced (III)
8.4. Recurrent / Metastatic
9. Minimally Invasive Treatment of Lung Cancer Market, by Procedure Type
9.1. Introduction
9.2. Tumor Resection / Lobectomy
9.3. Wedge Resection
9.4. Segmentectomy
9.5. Ablative Therapy
10. Minimally Invasive Treatment of Lung Cancer Market, by Guidance / Imaging
10.1. Introduction
10.2. CT-Guided
10.3. Fluoroscopy-Guided
10.4. Bronchoscopic-Guided
10.5. Ultrasound-Guided
11. Minimally Invasive Treatment of Lung Cancer Market, by End-User
11.1. Introduction
11.2. Hospitals & Cancer Centers
11.3. Thoracic Surgery Units
11.4. Interventional Pulmonology Units
11.5. Oncology Research Institutes
12. Minimally Invasive Treatment of Lung Cancer Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Minimally Invasive Treatment of Lung Cancer Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Minimally Invasive Treatment of Lung Cancer Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Accuray Incorporated
16.2. Ambu A/S
16.3. AngioDynamics Inc
16.4. Boston Scientific Corporation
16.5. Broncus Medical Inc
16.6. Conmed Corporation
16.7. Cook Medical LLC
16.8. Erbe Elektromedizin GmbH
16.9. Fujifilm Holdings Corporation
16.10. GE Healthcare Inc
16.11. HOYA Corporation
16.12. Intuitive Surgical, Inc.
16.13. Johnson & Johnson
16.14. Medtronic plc
16.15. Olympus Corporation
16.16. Pulmonx Corporation
16.17. Richard Wolf GmbH
16.18. Siemens Healthineers AG
16.19. Stryker Corporation
16.20. Teleflex Incorporated
16.21. Teleflex Incorporated
16.22. Telemed Systems Inc
16.23. Varian Medical Systems Inc
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Minimally Invasive Treatment of Lung Cancer Market, Years Considered for the Study
FIGURE 2. Global Minimally Invasive Treatment of Lung Cancer Market, Research Design
FIGURE 3. Global Minimally Invasive Treatment of Lung Cancer Market, Research Framework
FIGURE 4. Global Minimally Invasive Treatment of Lung Cancer Market, Data Triangulation
FIGURE 5. Global Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2025 vs 2032 (%)
FIGURE 7. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2025 vs 2032 (%)
FIGURE 9. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2025 vs 2032 (%)
FIGURE 11. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2025 vs 2032 (%)
FIGURE 13. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2025 vs 2032 (%)
FIGURE 15. Global Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Minimally Invasive Treatment of Lung Cancer Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Minimally Invasive Treatment of Lung Cancer Market Segmentation & Coverage
TABLE 2. Global Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 3. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 4. Global Video-Assisted Thoracoscopic Surgery (VATS) Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Video-Assisted Thoracoscopic Surgery (VATS) Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Video-Assisted Thoracoscopic Surgery (VATS) Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Robotic-Assisted Thoracic Surgery (RATS) Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Robotic-Assisted Thoracic Surgery (RATS) Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Robotic-Assisted Thoracic Surgery (RATS) Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Radiofrequency Ablation (RFA) Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Radiofrequency Ablation (RFA) Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Radiofrequency Ablation (RFA) Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Microwave Ablation (MWA) Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Microwave Ablation (MWA) Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Microwave Ablation (MWA) Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Cryoablation Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Cryoablation Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Cryoablation Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Stereotactic Body Radiation Therapy (SBRT) Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Stereotactic Body Radiation Therapy (SBRT) Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Stereotactic Body Radiation Therapy (SBRT) Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 23. Global Early-Stage (I-II) Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Early-Stage (I-II) Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Early-Stage (I-II) Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Locally Advanced (III) Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Locally Advanced (III) Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Locally Advanced (III) Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Recurrent / Metastatic Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Recurrent / Metastatic Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Recurrent / Metastatic Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 33. Global Tumor Resection / Lobectomy Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Tumor Resection / Lobectomy Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Tumor Resection / Lobectomy Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Wedge Resection Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Wedge Resection Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Wedge Resection Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Segmentectomy Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Segmentectomy Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Segmentectomy Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Ablative Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Ablative Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Ablative Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 46. Global CT-Guided Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global CT-Guided Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global CT-Guided Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Fluoroscopy-Guided Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Fluoroscopy-Guided Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Fluoroscopy-Guided Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Bronchoscopic-Guided Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Bronchoscopic-Guided Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Bronchoscopic-Guided Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Ultrasound-Guided Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Ultrasound-Guided Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Ultrasound-Guided Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 59. Global Hospitals & Cancer Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Hospitals & Cancer Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Hospitals & Cancer Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Thoracic Surgery Units Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Thoracic Surgery Units Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Thoracic Surgery Units Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Interventional Pulmonology Units Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Interventional Pulmonology Units Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Interventional Pulmonology Units Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Oncology Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Oncology Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Oncology Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Minimally Invasive Treatment of Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 78. North America Minimally Invasive Treatment of Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. North America Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 80. North America Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 81. North America Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 82. North America Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 83. North America Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 84. Latin America Minimally Invasive Treatment of Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Latin America Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 86. Latin America Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 87. Latin America Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 88. Latin America Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 89. Latin America Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 90. Europe Minimally Invasive Treatment of Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Europe Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 92. Europe Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 93. Europe Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 94. Europe Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 95. Europe Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 96. Middle East Minimally Invasive Treatment of Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Middle East Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 98. Middle East Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 99. Middle East Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 100. Middle East Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 101. Middle East Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 102. Africa Minimally Invasive Treatment of Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Africa Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 104. Africa Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 105. Africa Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 106. Africa Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 107. Africa Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 108. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. ASEAN Minimally Invasive Treatment of Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. ASEAN Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 111. ASEAN Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 112. ASEAN Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 113. ASEAN Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 114. ASEAN Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 115. GCC Minimally Invasive Treatment of Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. GCC Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 117. GCC Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 118. GCC Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 119. GCC Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 120. GCC Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 121. European Union Minimally Invasive Treatment of Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. European Union Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 123. European Union Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 124. European Union Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 125. European Union Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 126. European Union Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 127. BRICS Minimally Invasive Treatment of Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. BRICS Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 129. BRICS Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 130. BRICS Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 131. BRICS Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 132. BRICS Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 133. G7 Minimally Invasive Treatment of Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. G7 Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 135. G7 Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 136. G7 Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 137. G7 Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 138. G7 Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 139. NATO Minimally Invasive Treatment of Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. NATO Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 141. NATO Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 142. NATO Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 143. NATO Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 144. NATO Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 145. Global Minimally Invasive Treatment of Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 146. United States Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 147. United States Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 148. United States Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 149. United States Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 150. United States Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 151. United States Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 152. Canada Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 153. Canada Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 154. Canada Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 155. Canada Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 156. Canada Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 157. Canada Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 158. Mexico Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 159. Mexico Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 160. Mexico Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 161. Mexico Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 162. Mexico Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 163. Mexico Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 164. Brazil Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 165. Brazil Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 166. Brazil Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 167. Brazil Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 168. Brazil Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 169. Brazil Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 170. United Kingdom Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 171. United Kingdom Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 172. United Kingdom Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 173. United Kingdom Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 174. United Kingdom Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 175. United Kingdom Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 176. Germany Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 177. Germany Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 178. Germany Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 179. Germany Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 180. Germany Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 181. Germany Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 182. France Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 183. France Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 184. France Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 185. France Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 186. France Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 187. France Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 188. Russia Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 189. Russia Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 190. Russia Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 191. Russia Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 192. Russia Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 193. Russia Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 194. Italy Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 195. Italy Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 196. Italy Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 197. Italy Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 198. Italy Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 199. Italy Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 200. Spain Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 201. Spain Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 202. Spain Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 203. Spain Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 204. Spain Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 205. Spain Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 206. China Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 207. China Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 208. China Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 209. China Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 210. China Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 211. China Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 212. India Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 213. India Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 214. India Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 215. India Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 216. India Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 217. India Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 218. Japan Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 219. Japan Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 220. Japan Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 221. Japan Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 222. Japan Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 223. Japan Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 224. Australia Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 225. Australia Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 226. Australia Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 227. Australia Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 228. Australia Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 229. Australia Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 230. South Korea Minimally Invasive Treatment of Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 231. South Korea Minimally Invasive Treatment of Lung Cancer Market Size, by Treatment Modality, 2017-2032 (USD Million)
TABLE 232. South Korea Minimally Invasive Treatment of Lung Cancer Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 233. South Korea Minimally Invasive Treatment of Lung Cancer Market Size, by Procedure Type, 2017-2032 (USD Million)
TABLE 234. South Korea Minimally Invasive Treatment of Lung Cancer Market Size, by Guidance / Imaging, 2017-2032 (USD Million)
TABLE 235. South Korea Minimally Invasive Treatment of Lung Cancer Market Size, by End-User, 2017-2032 (USD Million)
TABLE 236. Global Minimally Invasive Treatment of Lung Cancer Market Share, by Key Player, 2025
TABLE 237. Global Minimally Invasive Treatment of Lung Cancer Market, Key Experts

Companies Mentioned

  • Accuray Incorporated
  • Ambu A/S
  • AngioDynamics Inc
  • Boston Scientific Corporation
  • Broncus Medical Inc
  • Conmed Corporation
  • Cook Medical LLC
  • Erbe Elektromedizin GmbH
  • Fujifilm Holdings Corporation
  • GE Healthcare Inc
  • HOYA Corporation
  • Intuitive Surgical, Inc.
  • Johnson & Johnson
  • Medtronic plc
  • Olympus Corporation
  • Pulmonx Corporation
  • Richard Wolf GmbH
  • Siemens Healthineers AG
  • Stryker Corporation
  • Teleflex Incorporated
  • Teleflex Incorporated
  • Telemed Systems Inc
  • Varian Medical Systems Inc

Related Topics

Related Reports

Minimally Invasive Treatment of Lung Cancer Market Report 2026 - Product Image

Minimally Invasive Treatment of Lung Cancer Market Report 2026

  • Report
  • 250 Pages
  • Global
From
South & Central America Lung Cancer Therapy Market Forecast to 2030 - Regional Analysis - By Therapy Type, Indication, and End User - Product Image

South & Central America Lung Cancer Therapy Market Forecast to 2030 - Regional Analysis - By Therapy Type, Indication, and End User

  • Report
  • 74 Pages
From
Europe Lung Cancer Therapy Market Forecast to 2030 - Regional Analysis - By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), and End User (Hospitals, Oncology Clinics, Research Centers, and Others) - Product Image

Europe Lung Cancer Therapy Market Forecast to 2030 - Regional Analysis - By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), and End User (Hospitals, Oncology Clinics, Research Centers, and Others)

  • Report
  • 92 Pages
  • Europe
From
Lung Cancer Therapy Market: Analysis By Treatment Method, By Therapy Type, By Indication, By End-User, By Region Size and Trends and Forecast up to 2029 - Product Image

Lung Cancer Therapy Market: Analysis By Treatment Method, By Therapy Type, By Indication, By End-User, By Region Size and Trends and Forecast up to 2029

  • Report
  • 184 Pages
  • Global
From
Lung Cancer Therapy Market Size and Forecasts 2020 - 2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type, Indication, End User, and Geography - Product Image

Lung Cancer Therapy Market Size and Forecasts 2020 - 2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type, Indication, End User, and Geography

  • Report
  • 206 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.